SOPHiA GENETICS’s (SOPH) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of SOPHiA GENETICS (NASDAQ:SOPH) in a research report report published on Monday,Benzinga reports. They currently have a $14.00 price target on the stock.

SOPH has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Friday, July 17th. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Finally, BTIG Research lifted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $10.00.

SOPHiA GENETICS Trading Down 0.4%

Shares of SOPHiA GENETICS stock opened at $7.06 on Monday. SOPHiA GENETICS has a fifty-two week low of $3.75 and a fifty-two week high of $8.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. The company has a market capitalization of $592.26 million, a P/E ratio of -6.14 and a beta of 0.95. The company has a fifty day moving average of $7.97 and a 200 day moving average of $6.22.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The business had revenue of $23.31 million during the quarter, compared to analysts’ expectations of $21.72 million. On average, sell-side analysts anticipate that SOPHiA GENETICS will post -0.77 earnings per share for the current fiscal year.

Insider Transactions at SOPHiA GENETICS

In related news, CEO Ross Muken sold 9,838 shares of the company’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $79,982.94. Following the completion of the transaction, the chief executive officer owned 660,391 shares in the company, valued at approximately $5,368,978.83. This represents a 1.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Chairman Jurgi Camblong sold 40,172 shares of the firm’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $8.13, for a total transaction of $326,598.36. Following the transaction, the chairman directly owned 3,395,650 shares of the company’s stock, valued at $27,606,634.50. The trade was a 1.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 300,043 shares of company stock valued at $2,256,756. 4.88% of the stock is currently owned by corporate insiders.

Institutional Trading of SOPHiA GENETICS

Several hedge funds have recently bought and sold shares of SOPH. First Dallas Securities Inc. purchased a new position in shares of SOPHiA GENETICS during the first quarter valued at about $50,000. Royal Bank of Canada increased its holdings in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock worth $96,000 after purchasing an additional 18,781 shares during the last quarter. AXQ Capital LP bought a new stake in shares of SOPHiA GENETICS in the second quarter worth about $119,000. Silverberg Bernstein Capital Management LLC lifted its position in shares of SOPHiA GENETICS by 8.7% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock worth $257,000 after buying an additional 4,155 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in shares of SOPHiA GENETICS in the second quarter worth about $567,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.